Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azetukalner versus placebo in moderate-to-severe major depressive disorder
2025-523202-32-00Phase 3Suspended
- Sponsor
- Xenon Pharmaceuticals
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Azetukalner with Placebo (2 arms). Primary endpoint: Change from baseline in HAMD-17 total score at Week 6. Started Feb 2026; status: suspended.
02
Drugs
azetukalner
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2025-523202-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523202-32-00.